Valvular Heart Disease: New Strategies

Las Vegas

FOURTH SCIENTIFIC SESSION HEART VALVE SOCIETY OF AMERICA

May 5-7, 2008
Bellagio Resort
Las Vegas, Nevada

Abstract and Meeting Information

Presented by:
Mayo Clinic College of Medicine and Heart Valve Society of America
Dear Colleague,

We would like to invite you to join us for the upcoming Valvular Heart Disease: New Strategies, which is the Fourth Annual Meeting for the Heart Valve Society of America (HVSA). Valvular heart diseases are among the most prominent cause of heart failure and premature cardiac death. It is estimated that more than 10 million Americans have some type of heart valve abnormality and in approximately five million the disease is moderate to severe. Three to four million will require surgery at some time in their lives. These numbers will grow as the population ages.

Valvular Heart Disease: New Strategies will provide state-of-the-art information for cardiologists, cardiothoracic surgeons and other physicians on how to deal with this emerging public health problem.

Join us in Las Vegas in 2008 for a premier education opportunity on valvular heart disease.

Sincerely,
Maurice Sarano, M.D.
Hartzell Schaff, M.D.
Thomas Orszulak, M.D.
A. Jamil Tajik, M.D.

PROGRAM HIGHLIGHTS

• Current criteria for surgical intervention
• Predictors of prognostically important deterioration among common lesions
• Emerging role of pacemaker therapy for mitral regurgitation
• Controversial role of drug prophylaxis for asymptomatic patients
• Current status and results for percutaneous valve replacement and repair techniques
• Anti-coagulation strategy early and late for valve replacement
• Impact of age on morbidity and mortality in valve surgery; considerations for surgical candidacy
• Case based study of valve disease management
• Technical how-to for surgical, interventional, and imaging procedures

COURSE DESCRIPTION

Valvular Heart Disease: New Strategies will provide a comprehensive, state-of-the-art, panorama of the new pathophysiologic insights, diagnostic methods, surgical and medical therapeutic approaches for valvular heart diseases and project the new strategies available. Valvular heart disease is a major world-wide problem despite the decline of rheumatic heart disease due to the emergence of new causes of valve diseases and the expected aging of the population in the new millennium.

Cardiologists and cardiac surgeons, world-renowned experts in valvular heart diseases, will present current emerging information. The program will provide expert review of new types of surgical interventions of the latest progress in reparative techniques and of the new prostheses available. The alternative options of medical treatment with new and potent drugs and of percutaneous catheter-based interventions with newly developed devices will be discussed. The controversial issue of intervention in asymptomatic patients and the new insights in the selection process for this type of patient will be debated. The daunting problem of left ventricular dysfunction due to valvular heart disease and its analysis from bench to bedside will be discussed.

Practical education will be given with breakout sessions specifically geared for surgeons, interventional cardiologists, and non-invasive cardiologists. The latest news in research will be provided by moderated poster sessions.

Formal lectures, panel discussions, extensive case studies and accessible faculty members will facilitate the exchange of information during the program.
ABSTRACT SUBMISSIONS

Valvular Heart Disease: New Strategies and the Heart Valve Society of America will provide the opportunity for authors to compete to present research in poster format on Tuesday, May 6, 2008.

It is the policy of the Mayo School of CME to ensure fair balance, independence, objectivity and scientific rigor in its entire sponsored program. All poster presenters are expected to disclose to participants any real or apparent conflict of interest related to the content of their poster. Authors chosen to present posters will be required to sign a conflict of interest disclosure form to that effect. Submissions should identify any authors who may have a possible conflict of interest by placing an asterisk next to his/her name.

All submissions must be received by 5 p.m., March 24, 2008. Authors will be contacted the week of April 4, 2008 regarding action on their abstracts.

Abstract Format Instructions:
1. Dimensions of the abstract should be no greater than 4.5" width x 6.5" (11.4 cm x 16.5 cm) and should be typed in standard 12 point Times New Roman font.
2. Type all abstracts in English.
3. Abstract title should appear in bold, uppercase letters. Do not use abbreviations in the title.
4. Using italics, list the names of all authors (place an asterisk next to the primary author) and the institution, city, and state where the work was done.
5. Leave space (one line) after the list of authors and begin typing the main body of the abstract.
6. Indent the first line of each paragraph of the abstract by three spaces.
7. Type single-spaced.
8. Send a hard copy and a computer file of the abstract or send as an e-mail attachment to: cvcme@mayo.edu
9. Multiple submissions of the same abstract will not be processed.
10. Abstracts that do not follow the above outlined format will not be accepted.

Submit abstracts and registration to:
Cardiovascular CME
Mayo Clinic
200 First Street SW, GO 6-138
Rochester, MN 55905

Phone: (507) 266-0677
E-Mail: cvcme@mayo.edu

Reception and Poster Review – May 6, 2008

Attendees and their guest(s) are cordially invited to join the course faculty for the Poster Review on Tuesday, May 6, 2008. Pre-registration is requested.
HEART VALVE SOCIETY OF AMERICA (HVSA)

This is the Fourth Annual Scientific Meeting of The Heart Valve Society of America (and Heart Valve Trialists Society).

The Society has been formed to:

• advance development of new knowledge regarding valvular heart diseases through promotion, organization and support for research (basic, pre-clinical, clinical, and epidemiological);
• facilitate transfer of research results to clinical practice; and,
• promote dissemination of knowledge about valvular heart diseases to medical, scientific, and general audiences.

Membership is open to physicians, non-physician researchers, other medical professional and students involved in the field, as well as individuals who work for corporations, academic and service institutions and foundations interested in valvular heart disease.

More information on the Society, including a membership application can be found on the HVSA web site: www.heartvalvesocietyofamerica.org.

DATE AND LOCATION

The Valvular Heart Disease: New Strategies program will be held May 5 - 7, 2008. The course will be held at the Bellagio Resort in Las Vegas, Nevada. The program will be located in the Tower Ballroom.

Attending Valvular Heart Disease: New Strategies allows participants to experience education and enjoy the dynamic location of Las Vegas. After the session, take advantage of world class entertainment and shows or experience one of the many culinary delights the city has to offer. The Bellagio is located in the heart of the city and offers many unique opportunities to enjoy in your free time such as attending the Cirque du Soleil “O” show, being pampered at the spa, the Botanical Conservatory, and an art gallery on-property. A must see is also the dancing waters at the Bellagio to make your visit complete.

CREDIT

College of Medicine, Mayo Clinic is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

College of Medicine, Mayo Clinic designates this educational activity for a maximum of 18.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
REGISTRATION

To register, complete the attached registration form and return by mail or fax. The registration fee includes tuition, comprehensive course syllabus, continental breakfasts, break refreshments, reception, and lunch. Early registration is strongly advised. A letter of confirmation will be sent upon receipt of payment and completed registration form. Please present the confirmation letter when checking in at the meeting registration desk.

CANCELLATION POLICY

Your registration fee, less a $100 administrative fee, will be refunded when written notification is received by the Cardiovascular Continuing Medical Education Office before April 15, 2008 (fax#: 507-538-0146). No refunds will be made after April 15, 2008.

Mayo School of CME reserves the right to cancel or postpone any course due to unforeseen circumstances. In the unlikely event Mayo School of CME must cancel or postpone this course, Mayo School of CME will refund the registration fee, but is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.

LODGING ACCOMMODATIONS

A block of guestrooms have been reserved with special rates at the Bellagio. To ensure accommodations and the discounted rate, please make your reservations by April 4, 2008. Reservations may be made by calling 888-987-6667 and identifying yourself as a participant of the Mayo Clinic Valvular Heart Disease conference. Early reservations are recommended since the room block may sell out prior to April 4th.

Bellagio
3600 Las Vegas Blvd South
Las Vegas, NV
Phone: 888-987-6667
Rates: $249 single/double

You may also wish to visit the Las Vegas Convention and Visitors Bureau website (www.visitlasvegas.com) for additional activities and information on this destination. Lodging arrangements are the sole responsibility of the individual registrant.

FACULTY

Course Directors
Maurice E. Sarano, M.D.  Hartzell V. Schaff, M.D.
Thomas A. Orszulak, M.D.  A. Jamil Tajik, M.D.

Mayo Cardiovascular Disease Faculty
Martin D. Abel, M.D.
Joseph L. Blackshear, M.D.
Charles J. Bruce, M.D.
Krishnaswamy Chandrasekaran, M.D.
Beth A. Eichhorn, R.N.
Joseph F. Maalouf, M.D.
Sunil V. Mankad, M.D.
Hector I. Michelena, M.D.
Vuyisile T. Nkomo, M.D.
Guy S. Reeder, M.D.
Charanjit S. Rihal, M.D.  – Continued on next page.
FACULTY - CONTINUED

Mayo Cardiovascular Surgery Faculty
Richard C. Daly, M.D.
Rakesh M. Suri, M.D., D.Phil.
Thoralf M. Sundt, III, M.D.

Guest Faculty
Cary W. Akins, M.D.
A. J. Basnadjian, M.D.
Raoul Bonan, M.D.
Robert O. Bonow, M.D.
Jeffrey S. Borer, M.D.
Blase A. Carabello, M.D.
Thierry P. Carrel, M.D.
W. Randolph Chitwood, Jr., M.D.
Jean G. Dumesnil, M.D.
Ted Feldman, M.D.
Francesco Grigioni, M.D., Ph.D.
Howard C. Herrmann, M.D.
Judy W. Hung, M.D.
Friedrich W. Mohr, M.D.
Ramda Pai, M.D.
Philippe Pibarot, M.D.
Nalini Rajamannan, M.D.
Nicholas G. Smedira, M.D.
William J. Stewart, M.D.
Christophe Tribouilloy, M.D.
Alec S. Vahanian, M.D.

The Heart Valve Society
of America Program Committee:
Cary W. Akins, M.D.
Robert O. Bonow, M.D.
Jeffrey S. Borer, M.D.
Blase A. Carabello, M.D.
O. Wayne Ison, M.D.
Jagat Narula, M.D.
Maurice E. Sarano, M.D.
Mark Starling, M.D.
A. Jamil Tajik, M.D.

FACULTY DISCLOSURE

As a provider accredited by ACCME, Mayo Foundation must ensure balance, independence, objectivity and scientific rigor in its educational activities. All faculty participating in a Mayo Foundation activity are required to disclose commitments to and/or relationships with pharmaceutical companies, biomedical device manufacturers or distributors, or others whose products or services may be considered to be related to the subject matter of the educational activity. Faculty will also disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these commitments and/or relationships will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentation.
MONDAY, MAY 5, 2008

7:00 am  Registration
7:55 am  Welcome and Course Description
Course Directors
8:00 am  Special Lecture: Comprehensive Imaging for Valvular Heart Disease is the Way of the Future
Jagat Narula, M.D.

Organic Mitral Regurgitation: Diagnosis and Management
Drs. Thomas A. Orszulak and Jagat Narula presiding

8:15 am  The LV in Mitral Regurgitation: How Important is it?
Dr. Robert O. Bonow
8:30 am  Natural History of Asymptomatic MR: Does It Justify Surgery or Vasodilators?
Dr. Maurice E. Sarano
8:45 am  PISA or Vena Contracta or Jet Size for MR: The Guidelines of The ASE
Dr. Christophe Tribouilloy
9:00 am  Atrial Fibrillation Complicating Severe MR, Surgical Management
Dr. Hartzell V. Schaff
9:15 am  Mitral Valve Repair: From Sternotomy to Robotic Surgery
W. Randolph Chitwood, Jr., M.D.
9:30 am  Subvalvular Support for Mitral Valve Repair: The Thorascopic Approach
Dr. Friedrich W. Mohr
9:45 am  Repair of Myxomatous Mitral Valve Disease: Techniques and Outcomes
Dr. Rakesh M. Suri
10:00 am Panel Discussion
Drs. Bonow, Sarano, Tribouilloy, Schaff, Chitwood, Mohr and Suri
Moderator: Dr. Orszulak
10:20 am Refreshment Break

Mitral Valve Diseases: Case Studies
Drs. A. Jamil Tajik and Cary W. Akins, presiding

10:40 am Mitral and Tricuspid Valve Illustrative Cases
Endocarditis .......................... Dr. K. Chandrasekaran
MR Presenting as AF .................. Dr. Joseph Blackshear
Ischemic MR ......................... Dr. Christophe Tribouilloy
3D Imaging for Mitral Valve Disease .......... Dr. Sunil Mankad
Severe TR - Repair .................. Dr. William J. Stewar
Flail Leaflet – Elderly ................ Dr. Thoralf M. Sundt, III
Radiation-Induced MR .............. Dr. Charles J. Bruce
HOCM and MR ...................... Dr. Vuyisle T. Nkomo

12:40 pm Lunch

Valvular Interventional Symposium
Moderators: Drs. Hartzell V. Schaff and Maurice E. Sarano

1:45 pm Mitral and Tricuspid Illustrative Case Session
Balloon Mitral Valvuloplasty .............. Dr. Alec Vahanian
Percutaneous Alfieri I ................... Dr. Ted Feldman
Percutaneous Mitral Annuloplasty I ....... Dr. Charanjit Rihal
Percutaneous Repair by the Surgeon? ...... Dr. Richard C. Daly
ASD Closure for Hypoxemic TR .......... Dr. Guy S. Reeder
Minimally Invasive MV Repair .......... Dr. Rakesh Suri
Program Schedule

3:45 pm Refreshment Break

3:45 pm Aortic and Pulmonary Illustrative Case Session
Aortic Balloon Valvuloplasty  Dr. Ted Feldman
AVR-Edwards  Dr. Alec Vahanian
AVR-Core Valve  Dr. Raoul Bonan
Percutaneous AVR-The Technical Tricks Dr. Howard Herrmann
Percutaneous AVR By The Surgeon  Dr. Friedrich W. Mohr
Periprosthetic Regurgitation  Dr. Charanjit Rihal

4:15 pm Adjourn

TUESDAY, MAY 6, 2008

7:00 am Continental Breakfast

Aortic Stenosis
Drs. Hartzell V. Schaff and Friedrich W. Mohr, presiding

7:30 am Calcific Aortic Stenosis: Pathophysiologic Insights, Medical Therapy
Dr. Nalini M. Rajamannan

7:45 am Comprehensive Assessment of Severity of Aortic Stenosis by Doppler and CT: State of the Art
Dr. Joseph F. Maalouf

8:00 am Natural History and Progression of AS: New Insights
Dr. Ramda Pai

8:15 am Management of Severe Aortic Stenosis and Associated Mitral Valve Regurgitation
Dr. Thierry Carrel

8:30 am Severe AS with Low-Gradient: Diagnosis and Management
Dr. Philippe Pibarot

8:45 am Asymptomatic Severe AS: Candidates for Early Surgery?
Dr. A. Jamil Tajik

9:00 am Durability of Bioprosthetic Valves: What Can We Really Expect?
Dr. Nicholas G. Smedira

9:15 am Which Patients are High Risk for Aortic Valve Replacement and What Procedures Should be Used?
Dr. Hartzell V. Schaff

9:30 am Panel Discussion
Drs. Rajamannan, Maalouf, Pai, Carrel, Pibarot, Tajik and Smedira
Drs. Schaff and Mohr moderators

9:55 am Refreshment Break

Aortic Regurgitation and Aortic Root Disease
Drs. A. Jamil Tajik and Nicholas G. Smedira, presiding

10:30 am Quantitation of Aortic Regurgitation: New Methods-Implications for Outcome
Dr. Judith W. Hung

10:45 am Natural History of AR - Timing of Surgery and Medicine in Asymptomatic Patients
Dr. Jeffrey S. Borer

11:00 am LV in Aortic Regurgitation
Dr. Blase A. Carabello

11:15 am Aortic Valve Repair in Tricuspid and Bicuspid Valves
Dr. Hartzell V. Schaff
11:30 am  Annulo-Aortic Ectasia and Marfan’s: Current Management
          Dr. Thoralf M. Sundt, III
11:45 am  Panel Discussion
          Drs. Borer, Carabello, Hung, Schaff, and Sundt
          Drs. Tajik and Smedira, moderators
12:15 pm  Lunch

**Aortic Valve Diseases: Case Studies**
Drs. Maurice E. Sarano and Jeffrey S. Borer, presiding
1:15 pm  Aortic Valve Disease Illustrative Cases
          Endocarditis  Dr. William J. Stewart
          A5 and AF  Dr. Ramda Pai
          A5 Low Output  Dr. Christophe Tribouilloy
          AR and Low EF  Dr. Hector I. Michelea
          Aortic Prosthetic Dysfunction  Dr. A. J. Basmadjian
          AR 3-D Imaging  Dr. Suri Mankad
          Is this Prosthesis Functioning Normally?  Dr. Jean Dumesnil
          AR Marfan  Dr. Rakesh M. Suri
3:15 pm  Refreshment Break

**Ischemic and Functional Mitral Surgery: The Next Frontier?**
Drs. Hartzell V. Schaff and Thierry P. Carrel, presiding
3:45 pm  Mechanism of Chronic Ischemic MR: New Insights
          Dr. Maurice E. Sarano
4:00 pm  Outcome Implications of Ischemic/Functional MR
          Dr. Francesco Grigioni
4:15 pm  Ischemic/Functional MR: Surgical Failures-Pacing Rx: How Does it Happen?
          Dr. Judith W. Hung
4:30 pm  When is Revascularization Alone Sufficient for Ischemic MR?
          Dr. Cary W. Akins
4:45 pm  Annuloplasty and Adjunctive Procedures for Ischemic MR
          Dr. Thoralf M. Sundt, III
5:00 pm  Functional Tricuspid Regurgitation: Assessment and Outcome Implications
          Dr. Vuyisile T. Nkomo
5:15 pm  Functional Tricuspid Regurgitation: When and How to Treat Surgically
          Dr. Thomas A. Orszulak
5:30 pm  Panel Discussion
          Drs. Sarano, Grigioni, Hung, Akins, Sundt, Nkomo, and Orszulak
          Drs. Schaff and Carrel, moderators
5:45 pm  Heart Valve Society of America – Business Meeting
6:00 pm  Adjourn

**Poster Session with Wine and Cheese**
6:15 pm  VHD Poster Review
          Surgical Posters  Drs. Schaff, Mohr, and Akins
          Echo Posters  Drs. Levine, Nkomo, and Mankad
          Outcomes Posters  Drs. Sarano, Borer, and Stewart
          Basic Science Posters  Drs. Carabello, Rajamannan, and Narula
          Nursing Posters  Dr. Dumesnil and Ms. Eichhorn
7:30 pm  Adjourn
WEDNESDAY, MAY 7, 2008

7:30 am  Continental Breakfast

8:00 - 11:30 am  Break-Out Sessions: Practically How To Do It

A. Surgical Session:
How Do I Do A Valve Repair, How Do You Learn It
Moderators: Drs. Hartzell V. Schaff and M Abel
Panel: Drs. Cary Akins, Thoralf Sundt, Friedrich Mohr, Nicholas Smedira, Thierry Carrel, Richard Daly, Martin Abel, Rakesh Suri, and Thomas Orszulak

This session will be lead by leading cardiovascular surgeons that will present illustrative cases demonstrating techniques used in valvular heart disease surgery.

B. Non-Invasive Session:
How Do I Diagnose and Quantitatively Assess VHD
Moderators: Drs. Maurice E. Sarano and Jean G. Dumesnil

This session will focus on the diagnosis and assessment of valvular heart disease integrating non-invasive imaging modalities.

11:30 am  Adjourn
Valvular Heart Disease: New Strategies
May 5–7, 2008 • Las Vegas, Nevada

Mail or FAX this completed registration form to:
Mayo Cardiovascular CME
200 First Street SW
ATTN: Deborah Feils - Gonda 6
Rochester, MN 55905

Telephone: 800-283-6296
or 507-266-0677
FAX: 507-538-0146
E-mail: cvcme@mayo.edu
Website: www.mayo.edu/cme

PAYMENT

Registration Before 4/28/08 Registration After 4/28/08
Physicians/PhDs: $575 $625 $________________
HVSA Members: $550 $600 $________________
Other Healthcare Professionals Reduced Fee
$400 $450 $________________

*Registrants in the reduced fees category are required to submit with the registration form proof of licensure, a business card, or a letter on official letterhead and signed by a department supervisor verifying status.

Total Payment Enclosed: $________________

Payment Method
☐ Check (make checks payable to Mayo Clinic)
☐ Credit Card: ☐ Visa ☐ MasterCard ☐ Discover (Note: American Express is not accepted)

Card Number ____________________________
Expiration Date _________________________

Signature ____________________ Date ____________
Valvular Heart Disease: New Strategies
May 5-7, 2008
Bellagio Resort • Las Vegas, Nevada

COURSE HIGHLIGHTS
• Current criteria for surgical intervention
• Cell and molecular biology of valve disease
• Predictors of prognostically important deterioration among common lesions
• Emerging role of pacemaker therapy for mitral regurgitation
• Controversial role of drug prophylaxis for asymptomatic patients
• Anti-coagulation strategy early and late for valve replacement
• Current status and results for percutaneous valve replacement and repair techniques
• Surgical and catheter-based therapy for atrial fibrillation associated with mitral valve disease
• Impact of age on morbidity and mortality in valve surgery; considerations for surgical candidacy
• Case based study of valve disease management
• Technical how-to for surgical, interventional, and imaging procedures

E-mail: cvcme@mayo.edu • Phone: 507-266-0677